Myeloproliferative Neoplasms | Specialty

The OncLive Myeloproliferative Neoplasms condition center is a comprehensive resource for clinical news and expert insights on myeloproliferative neoplasms, including myelofibrosis, polycythemia vera, and essential thrombocythemia. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in myeloproliferative neoplasms.

Challenges Remain in Treatment of Accelerated Phase Myeloproliferative Neoplasms

September 10th 2021

Treating patients with accelerated phase myeloproliferative neoplasm is an ongoing therapeutic challenge, due to the lack of standard treatment approaches, according to an expert.

Dr. Verstovsek Discusses Research Efforts in Myelofibrosis-Related Anemia

September 10th 2021

Srdan Verstovsek, MD, PhD, discusses ongoing research in myelofibrosis-related anemia.

MYLOX-1 Trial Opens to Evaluate Novel Anti-Fibrotic Agent GB2064 in Myelofibrosis

September 3rd 2021

The phase 2a MYLOX-1 trial is evaluating GB2064, a novel, oral LOXL2 inhibitor, as a potential anti-fibrotic treatment option for patients with myelofibrosis.

Dr. Rampal on the Importance of Genomic Testing in Myelofibrosis

September 2nd 2021

Raajit K. Rampal, MD, PhD, discusses the importance of genomic testing in myelofibrosis.

Dr. Mauro on the Risks of Disease Progression in Myelofibrosis

August 31st 2021

Michael J. Mauro, MD, discusses the risks of disease progression in myelofibrosis.

Palbociclib/Ruxolitinib Combo Shows Preclinical Promise in Myelofibrosis

August 19th 2021

Palbociclib plus ruxolitinib led to normalized blood leukocyte counts, reduced splenomegaly, and significantly improved bone marrow fibrosis in JAK2 V617F and MPLW515L mouse models of myelofibrosis, suggesting that the combination could provide therapeutic benefit to patients with the malignancy.

Unmet Needs in Management of Myeloproliferative Neoplasms

August 18th 2021

Pankit Vachhani, MD, reacts to treatment limitations for health care professionals who care for patients with myeloproliferative neoplasms.

Selecting Therapy to Treat Myelofibrosis

August 18th 2021

Patient factors and disease characteristics that impact decisions to treat patients with myelofibrosis with ruxolitinib or fedratinib.

Ruxolitinib for Myelofibrosis: Treatment Considerations

August 18th 2021

Pankit Vachhani, MD, explains how to properly treat myelofibrosis using ruxolitinib based on data provided by key clinical trials like COMFORT-I and COMFORT-II.

Dr. Jamieson on the Importance of Treating at Diagnosis in Myelofibrosis

August 12th 2021

Catriona Jamieson, MD, PhD, discusses the importance of treating patients with myelofibrosis at diagnosis.

Momelotinib Improves Transfusion Independence Rates Vs Ruxolitinib in Anemic, JAK Inhibitor–Naïve Myelofibrosis

August 12th 2021

Jean-Jacques Kiladjian, MD, PhD, discusses the effectiveness of momelotinib compared with ruxolitinib in patients with myelofibrosis who have anemia and are naïve to JAK inhibitors.

Myelofibrosis: Treatment Planning and Management

August 11th 2021

Criteria and assessments that can be used to help clinicians select treatment and monitor patients on therapy for myelofibrosis.

Treatment Approaches for Myelofibrosis

August 11th 2021

Pankit Vachhani, MD, comments on goals of therapy for patients with myelofibrosis and highlights traditional treatment approaches.

Risk Stratification: Primary Myelofibrosis

August 11th 2021

An overview of risk stratification models available to assess and classify patients with primary myelofibrosis.

Rusfertide Could Represent New Therapeutic Option in Polycythemia Vera

August 6th 2021

Marina Kremyanskaya, MD, PhD, discussed the results of the phase 2 PTG-300-04 trial, which were presented at the European Hematology Association 2021 Virtual Congress, and the potential for rusfertide as a treatment option for patients with polycythemia vera.

Allogeneic HSCT Linked With Favorable Survival Outcomes in Myelofibrosis

August 5th 2021

Though there have been significant and recent therapeutic developments for patients with myelofibrosis, allogeneic hematopoietic stem cell transplant remains the sole curative therapeutic modality.

Dr. Mauro on Considerations for Early Treatment Initiation in Myelofibrosis

August 5th 2021

Michael J. Mauro, MD, discusses considerations for early treatment initiation in myelofibrosis.

Future Directions in the Treatment of Polycythemia Vera

August 4th 2021

A thought leader in hematologic malignancies provides key insights into the future of treatment for polycythemia vera by considering the potential role of treatment sequencing or combination therapy.

Ruxolitinib in PV: The RESPONSE-2 Trial

August 4th 2021

Jamile Shammo, MD, FASCP, FACP, continues her discussion of ruxolitinib for polycythemia vera by examining the results of the RESPONSE-2 trial and sharing personal experience managing toxicity in clinic.

Ruxolitinib in PV: The RESPONSE Trial

August 4th 2021

Renowned expert in the management of MPNs, Jamile Shammo, MD, FASCP, FACP, reviews the RESPONSE trial of ruxolitinib in patients with PV and discusses the agent’s safety and efficacy.